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Abstract 
Significant amounts of different tRNA molecules are present in retroviral particles, but one specific tRNA species functions as primer in reverse 
transcription. It is generally believed that the HIV-l virus uses the tRNALySv3 molecule as primer. This is based on sequence complementarity between 
the 3’ end of tRNAQ’“,’ and the primer-binding site (PBS) on HIV-I genomic RNA. Recent biochemical analyses indicated that tRNA”x3 is indeed 
incorporated into viral particles. Interestingly, tRNA’+y”,3 could not be detected in virions produced by HeLa-CD4’ cells [(1992) Biochem. Biophys. 
Res. Commun. 185, 1105-l 1151. In order to test whether alternative tRNA molecules can function as primer in HIV replication, we performed a 
series of experiments based on the observation that tRNA primer sequences are inherited by the viral progeny. We cultured HIV-l for prolonged 
periods of time in HeLa-CD4’ cells, but did not detect sequence changes in the PBS region. Furthermore, we found PBS-mutants to be replication- 
incompetent, again suggesting that HIV-l solely uses tRNAQ”,’ as primer. Most importantly, we obtained revertants of one such PBS-mutant, which 
had restored a wild-type PBS sequence. This tRNA’+‘“,’ -mediated repair demonstrates a general requirement for this primer in HIV-l reverse 
transcription. 
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1. Introduction 
The replicatio cycle of human immunodeficiency virus 
(HIV) and other retroviruses involves the reverse tran- 
scription of virion RNA into DNA, which then becomes 
integrated into the host cell genome (reviewed in [2]). The 
reverse transcription reaction is mediated by the virion- 
associated enzyme reverse transcriptase (RT) and a cellu- 
lar tRNA molecule is used as primer. The tRNA mole- 
cule associated with the genomic RNA by base-pairing 
of the 3’-terminal 1619 nucleotides of the primer with 
a complementary sequence in the viral genome, referred 
to as the primer-binding site (PBS). Some diversity exists 
with regard to the tRNA molecule used as primer by the 
different retroviruses. The vast majority of the mammal- 
ian retroviruses use tRNAh”, and avian retroviruses use 
tRNATp (reviewed in [3]). Both human T-cell leukemia 
virus types I and II utilize tRNAP”, and the HIV-l and 
HIV-2 sequences reveal a PBS corresponding to 
tRNALy”*3 [4] (see also Fig. 1A). This same tRNALy”s3 
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molecule, which is one of the major tRNALy” isoaccep- 
tors present in mammalian cells [5], is also used by mouse 
mammary tumor virus, while tRNALy”,‘,* is used by 
Mason-Pfizer monkey virus, Visna and Spuma retro- 
virus. The identity of only a few primer species was 
substantiated by biochemical studies on the amino-acid- 
acceptor properties, chromatographic behaviour and 
tRNA sequence (reviewed in [2]). 
Recent work by Jiang et al. [l] showed that tRNA’-ys*3 
is indeed present in HIV-l viral particles produced in 
T-lymphocytic cell lines. In general, retroviral particles 
do not exclusively contain genomic RNA and the corre- 
sponding tRNA primer, but in addition a large number 
of other tRNA molecules. Of the many tRNAs, the 
primer species is in tight association with the viral RNA, 
while most other tRNAs are referred to as free tRNA. 
The primer tRNALy”s3 was shown to be the major compo- 
nent of the genome-assosiated tRNA in HIV-l virions, 
which resisted dissociation from the HIV-l RNA at 
65°C [l]. Surprisingly, these authors were unable to de- 
tect tRNALyss3 in virions produced in HeLa-CD4’ cells. 
Instead, one tightly-associated and abundant RNA spe- 
cies was found that did not have the electrophoretic mo- 
bility of tRNALy”s3 and did not hybridize to tRNALy”s3- 
specific probes. These results may suggest hat HIV can 
replicate in HeLa-CD4’ cells using a primer other than 
tRNA”“x3. 
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2. Results and discussion 
We have tested primer-usage of HIV-l in HeLa-CD4’ 
cells by analyzing the PBS sequences of viruses that were 
cultured for a prolonged period of time in HeLa-CD4’ 
cells. The rational for this approach stems from the 
model for retroviral replication [6]. The model predicts 
that the sequence of the primer-binding site in proviruses 
is the copy DNA of the 3’ end of the priming tRNA 
species. This tRNA-copy is formed during strong-stop 
plus-strand DNA synthesis and most likely proceeds up 
to the first modified base in the tRNA (Am1 in Fig. 1A). 
Recent data of Rhim et al. [7] strongly support this as- 
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pect of the model. Thus, the PBS sequence is regenerated 
from the priming tRNA itself and usage of an alternative 
primer should lead to changes in the PBS sequence after 
one replication cycle. For instance, usage of tRNAP’” will 
generate HIV-l progeny with 8 nucleotide substitutions 
in the PBS and usage of one of the other lysine-accepting 
tRNAs will change the PBS at 5 positions (Fig. 1 B). Such 
altered PBS sequences will perfectly match the new 
primer in subsequent replication cycles. 
In order to allow viral replication in HeLa cells, we 
used the HeLa-CD4’ cell line that expresses the HIV-l 
receptor on its surface [8]. HeLa-CD4’ cells were in- 
fected with a HIV-l LA1 virus stock that was produced 
in T cells and virus replication was continued for many 
weeks by frequently passaging the cell-free virus onto 
fresh HeLa-CD4’ monolayers (see legend to Fig. 2 for 
experimental details). Since the viral stock was produced 
in T cells, the first round of reverse transcription in 
HeLa-CD4’ cells will use a tRNALy”s3 primer derived 
from T cells. Therefore, we analyzed viral sequences only 
after several passages in HeLa-CD4’ cells. The proviral 
DNA sequence obtained at this time point is shown in 
Fig. 2 (HeLal). We also analyzed multiple proviral se- 
quences after 32 passages in HeLa-CD4’ cells (HeLa2- 
6). The results clearly indicate that the PBSLyss3 sequence 
is not changed in proviral genomes recovered from 
HeLa-CD4’ cells. In addition, we tested the pool of pro- 
viral DNA for the presence of the NarIIKusI restriction 
site within the PBS sequence (GGCGCC). We could not 
detect NarIIKasI-resistant HIV sequences, which is con- 
sistent with the absolute conservation of the binding site 
for tRNALy”,3. 
It cannot a priori be excluded that selection of a new 
primer tRNA in HeLa-CD4’ cells is coupled to the use 
of another PBS sequence at a different position on the 
t 
Fig. 1, Schematic representation of the PBS-tRNA interaction for the 
HIV virus. (A) The consensus genomic sequences of HIV-l and HIV-2 
are shown with the 1%nucleotide long PBS region in bold. Nucleotide 
variation in 20 HIV-l and 18 HIV-2 isolates (4) is indicated with the 
number of isolates having the particular sequence in superscript. Nucle- 
otide deetions are shown as A. The viral PBS sequence is shown base- 
paired to the 3’ end of the tRNALyS*’ primer. The tRNA nucleotide 
flanking the base-paired stretch is the methylated A”’ residue. The 
remaining part of the tRNA molecule is drawn as two stem-loop struc- 
tures, representing the anticodon- and D-arm, and the single-stranded 
5’ end. (B) Putative interactions of the HIV-l primer-binding site (PBS) 
with tRNAs other than tRNA Lys.s. This analysis was performed for the 
primer species frequently used by other retroviruses (tRNA’“, tRNATrp 
and tRNALy”.‘,“). The latter three tRNAs are represented by one se- 
quence because they have an identical 3’-terminus (5). The base-pair 
potential is indicated by dots and the total number of interactions is 
listed. (C) PBS-tRNA interaction for the wild-type PBS and mutants 
PBS-NS and PBS-KS. The 2- or 4-nucleotide deletion was introduced 
into the full-length HIV-l plasmid pLAI by digestion with endonu- 
cleases NarI or KasI, respectively, followed by digestion of the single- 
stranded 3’ ends with nuclease Sl and subsequent ligation. This se- 
quence modification was verified by sequence analysis. 
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Fig. 2. Nucleotide sequence of HIV-l proviral DNA obtained from HeLaCD4’ cells. Subconfluent monolayers of HeLa-CD4’ cells (approximately 
0.5 x lo6 cells in 2 ml medium per 24-well dish) were infected with a cell-free HIV-l LA1 virus that was obtained from DNA-transfected SupTl T 
cells. Viral replication was monitored by the appearance of syncytia and 100~1 of culture supernatant was passed twice a week onto a fresh monolayer 
of HeLaCD4’ cells. Proviral sequences were selectively amplified from total cellular DNA by PCR using a 5’ primer (NRE-B) in the U3 region of 
the LTR and a 3’ primer (Gag-3) in the gag gene. The DNA fragment was subcloned into pUC9 plasmid using unique restriction sites present in 
the primers and analyzed on an Applied Biosystems automatic sequencer. HeLal was isolated after 8 passages in HeLaCD4’ cells, and HeLa2-6 
were obtained after 16 weeks (32 passages). The nucleotide sequence of the input LA1 isolate is shown for comparison. The position of the 
transcriptional start site (+ l), PBSLy”,’ and gag start codon is indicated. For the HeLa2-6 clones, we sequenced a total of 3250 nucleotides and found 
15 base substitutions (not shown). This would suggest hat on average f 1 mutation is introduced per genome per passage, which is consistent with 
an error frequency of the RT enzyme of lo-“ (10). 
viral genome. We therefore analyzed sequences flanking 
the PBSLy”,3 region. The complete HIV-l leader region 
from the transcriptional start site at position +l up to 
position +385 within the gag reading frame was ana- 
lyzed. No major sequence alterations were observed in 
the HIV-l leader region of clones HeLal-6 compared to 
the input virus LA1 (Fig. 2). In addition, we found that 
the HeLa-adapted virus was able to initiate an infection 
in T cells (not shown). 
To formally prove the importance of the PBSLy”s3 se- 
quence for viral replication in HeLa cells, we constructed 
two mutant HIV-l genomes with a 2- or 4-nucleotide 
deletion in the PBS (Fig. lC, mutants PBS-NS and PBS- 
KS, respectively). The reduced basepairing potential of 
a mutant PBS with the 3’ end of tRNALyq3 is expected 
to interfere with initiation of reverse transcription [7,9]. 
Wild-type and mutant proviral DNAs were individually 
transfected into HeLa-CD4 cells and viral replication 
was monitored by visual inspection for syncytium forma- 
tion and quantitated by Gag p24 antigen levels released 
into the medium (Fig. 3). Replication of the wild-type 
virus proceeds at a rapid rate such that after 13 days of 
culture massive syncytia were observed and high levels 
of Gag p24 were measured in the supernatant. Although 
both mutants transiently produced virus, we did not 
measure subsequent viral replication. No infectious virus 
was produced in the PBS-KS transfection up to 38 days 
of culture. In contrast, a rapid increase in Gag p24 levels 
was detected in the PBS-NS culture at day 16. The super- 
natant of day 20 was used to infect fresh HeLa-CD4+ 
cells and the sequence of the PBS of the resulting pro- 
viruses was analyzed. It appeared that a reversion to the 
wild-type PBS sequence had taken place (four clones 
were analyzed). These results show that PBS-mutated 
viruses are unable to replicate in HeLa cells. The tran- 
sient production of normal levels of mutant virus shortly 
after transfection indicates that the PBS-mutation has no 
effect on virus production, e.g. protein synthesis or vir- 
ion assembly. Similar results were obtained in SupTl T 
cell transfections (data not shown). 
The molecular mechanism of reverse transcription 
predicts that a mildly mutated PBS can be repaired in 
one step during tRNA-mediated reverse transcription as 
long as the primer is able to anneal to the mutated viral 
genome [7]. This model can explain both the reversion 
seen for the PBS-NS mutant and the apparent failure to 
obtain revertants for the more severely mutated PBS-KS 
variant. Most importantly, the model predicts that the 
PBS sequence of progeny viruses corresponds to the se- 
quence of the 3’ end of the tRNA primer used. As de- 
scribed above, the viruses resulting from the PBS-NS 
transfection had regenerated the wild-type PBS se- 
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Fig. 3. Virus production upon transfection of wild-type (WT) and 
PBS-mutated HIV-l constructs PBS-NS and PBS-NK. HeLa-CD4’ 
cells were transfected with 10 pg DNA by the DEAE-dextran method. 
Virus-associated Gag p24 protein was measured in the culture superna- 
tant by elisa (note the logarithmic scale used to plot Gag p24 values). 
At day 20 the virus-containing supernatant of the PBS-NS culture was 
used to infect fresh HeLaCD4’ cells. Resulting proviral sequences were 
amplified by PCR using the 5’ U3 region primer 5’ CE and the 30 gag 
primer SK39. A Hi&III-ClaI fragment (position 77 to 376) was cloned 
into pSP73 (Promega) and sequenced as described in the legend of Fig. 
2. 
quence, which identifies tRNALy”s3 as primer for HIV-l 
reverse transcription in HeLa cells. 
The hypothesis that the HIV-l virus can use multiple 
tRNA primers in a cell-type dependent manner may have 
seem unlikely for several reasons. First, given the critical 
role for tRNALy”s3 in mRNA translation, it is hard to 
imagine that this tRNA is not available in HeLa cells. 
Second, the PBSLy”a3 sequence is well-conserved among 
20 HIV-l and 18 HIV-2 isolates (Fig. lA), although it 
should be noted that none of these viruses were isolated 
from HeLa cells. Third, there is little base-pair potential 
for other tRNAs on the HIV-l PBS (Fig. 1B). In addi- 
tion, recent data suggests that a primer tRNA can inter- 
act with retroviral RNA through additional base-pairing 
interactions outside the 18-bp PBS pairing, thereby in- 
creasing the selectivity of primer usage [ll-131. These 
arguments, combined with our experimental evidence, 
do strongly suggest hat tRNALy”,3 is the exclusive primer 
in HIV-l replication in both T cells and non-T cells. For 
the murine leukemia viruses, however, there is some evi- 
dence that alternative tRNAs ten serve as primer in 
retroviral replication. Colicelli and Goff [3] described a 
revertant of the Moloney murine leukemia virus contain- 
ing a 500 base-pair insert derived from the mouse 
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genome. The PBS was no longer complementary to the 
usual tRNAP’“, but had become a perfect 18-nucleotide 
match for tRNAG’“. Furthermore, retroviral viral vectors 
based on the AKV murine leukemia virus were recently 
shown to successfully transduce their genes in the pres- 
ence of a PBS specifying tRNA primers other than the 
normal tRNAP’” molecule [14]. Perhaps there is a more 
selective primer usage in HIV-l compared to the murine 
retroviruses. It is possible that this specificity reflects the 
selective binding of primer tRNA by the HIV-l reverse 
transcriptase nzyme [ 151 when compared to its murine 
homologue [ 161. 
The biochemical data reported by Jiang et al. [l] con- 
vincingly showed a dramatic different pattern of virus- 
associated tRNA in T cells versus HeLa cells. Most nota- 
bly, no tRNALy”f3 could be detected in the latter. Our 
results suggest hat at least one tRNALys,3 molecule is 
present in HeLa-produced virions because it is used as 
primer in reverse transcription. These combined data 
suggest hat HIV replication is not exclusively sensitive 
to the number of primer molecules incorporated into the 
virion. If we assume that the HIV-l reverse transcriptase 
is responsible for the specific incorporation of the primer 
tRNA [ 151 and that HIV- 1 reverse transcriptase is pres- 
ent in about 2-70 copies per virion as has been reported 
for other retroviruses [2], it follows that HIV-l virions 
contain an excess of 20-70 primer molecules. This sce- 
nario reconciles the biochemical and genetic data in that 
a severe reduction in tRNA content does not necessarily 
interfere with viral replication. In other words, it is pos- 
sible that HeLa cell-mediated packaging of HIV-l viri- 
ons results in the incorporation of less tRNALy”T3, with- 
out having an effect on the infectivity of the virions. 
Alternatively, it is possible that the reduced levels of 
virus-associated tRNALy”s3 in HeLa cells is responsible in 
part for the reduced growth kinetics of HIV-l in HeLa 
cells when compared to T cells. Finally, it remains of 
interest to identify the other non-primer tRNA species 
that are selectively packaged into retroviral particles [17- 
191, especially the abundant tRNA species in HeLa-de- 
rived HIV particles that was found in tight association 
with the RNA genome (1). 
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